Compare GSK plc (GSK) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tenet Healthcare Corporation — how do they compare? GSK plc trades at $52.67 (market cap $101.34B), while Tenet Healthcare Corporation trades at $198.64 (market cap $16.57B). The key difference: GSK plc is far larger — about 6.1× Tenet Healthcare Corporation's market cap, and GSK plc pays a 3.49% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| GSK | THC | |
|---|---|---|
Market Cap | $101.34B | $16.57B |
Sector | Health | Health |
52-Week High | $61.18 | $244.80 |
52-Week Low | $36.20 | $148.38 |
Enterprise Value | $121.95B | $26.81B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Tenet Healthcare (THC) trades at $199.10, up 8.39% over the past day, with strong fundamental metrics including a P/E of 10 and net income margin of 7.79%. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $4.82 surpassing the $4.17 estimate. Technical indicators show a bearish trend with support at $187 and resistance at $197, while analyst sentiment remains overwhelmingly positive with 26 buy ratings and a consensus price target of $235.88.
The outlook for THC is favorable due to robust earnings performance and attractive valuation, though near-term price volatility and competitive pressures in healthcare pose risks. Revenue growth is projected to increase from $21.3B in 2025 to $21.9B in 2026, supporting further upside if execution continues. Investors should monitor Q2 2026 earnings due July 24, 2026, for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
